Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29946979 | 0.85 | PDGFRA (0.59) | PDGFRACDK5TYRO3PDPK1JAK2 | |
| SCHEMBL2144184 | 0.85 | PDGFRA (0.59) | PDGFRACDK5TYRO3PDPK1JAK2 | |
| SCHEMBL3655093 | 0.81 | PRKCI (0.41) | HTTMAPTMEN1RAB9AKMT2A | |
| SCHEMBL12326828 | 0.79 | TDP1 (0.40) | MAPTMEN1RAB9AKMT2AGSK3B | |
| SCHEMBL1336984 | 0.79 | ADORA2A (0.59) | MAPK8HTTMAPTRAB9AADORA2A | |
| SCHEMBL1047954 | 0.78 | MAPK8 (0.44) | PDGFRACDK5TYRO3JAK2MAPK8 | |
| SCHEMBL9179915 | 0.78 | SCN9A (0.41) | MEN1RAB9AKMT2AGSK3BSLC2A1 | |
| SCHEMBL13106482 | 0.78 | MAPK8 (0.41) | PDGFRACDK5TYRO3PDPK1JAK2 | |
| SCHEMBL14879281 | 0.78 | PDGFRA (0.47) | PDGFRACDK5TYRO3PDPK1JAK2 | |
| SCHEMBL1585405 | 0.78 | GSK3B (0.37) | PDGFRACDK5TYRO3GSK3BSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-10-03 | — | — | US | disclosed |
| EP-3519409-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING HIV INFECTION | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4387609-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4367111-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-05-15 | — | — | EP | disclosed |
| CN-117999259-A | Iron death modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-117813086-A | Arylsulfonyl (hydroxy) piperidines as CCR6 inhibitors | 坎莫森特里克斯公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023116835-A1 | MULTI-PROTEIN DEGRADATION AGENT HAVING IMIDE SKELETON | 苏州开拓药业股份有限公司 | 2023-06-29 | — | — | WO | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| WO-2013159064-A1 | BENZOTHIAZOL- 6 -YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012064642-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| US-7632854-B2 | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2009-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | PDGFRA 152/4885CDK5 683/4885TYRO3 3633/4885 |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | PDGFRA 1176/4885CDK5 11/4885TYRO3 557/4885 |
| US-20240327393-A1 | FERROPTOSIS MODULATORS, PREPARATIONS, AND USES THEREOF | AIFM2, GPX1, GPX4 | PDGFRA 4063/4885CDK5 3138/4885TYRO3 4596/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | PDGFRA 359/4885CDK5 4272/4885TYRO3 782/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | PDGFRA 2967/4885CDK5 688/4885TYRO3 4496/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | PDGFRA 477/4885CDK5 917/4885TYRO3 4520/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | PDGFRA 1711/4885CDK5 2846/4885TYRO3 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.